Data presented at the European Society for Medical Oncology annual congress in Vienna, Austria linked the delay of pain progression the functional decline of men with the newly approved drug Zytiga. The data was derived from an additional anaylisis of the phase 3 trial (COU-AA-302) that led to the FDA approval of Zytiga. The FDA [...]
There was just a new site opened for the early/expanded access program for Alpharedin (Radium-235). The new site is at Stanford University, California. This makes a total of four sites, but most of them have not been adequately supported by the drug company, Bayer. Hopefully, this site will be better supported, but if it too [...]
One of the constant complaints I hear fro men with advanced prostate cancer that has become castrate resistant about Provenge (sipuleucel-T) is that the anticipated increase in overall survival is only 4.1 months and given the cost of $93,000 for the three infusions many men feel that cost does not justify the survival benefit. My [...]
The FDA has approved c11 choline Injection, a Positron Emission Tomography (PET) imaging agent, for use in men to detect prostate cancer recurrences and to locate specific body sites for follow-up tissue sampling, testing and treatment. The indicated use for c11 choline injection is men with elevated prostate specific antigen (PSA) levels after earlier primary [...]
On Wednesday, Johnson & Johnson said that the FDA will conduct a fast review of Zytiga as a treatment for men with advanced prostate cancer who have not received chemotherapy. The Food and Drug Administration has agreed to conduct a six-month review of Zytiga which should be completed in mid-December, 2012. According to representatives from [...]